BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22

• 

  ALS

  Patients Fight for Access to BrainStorm’s ALS Drug After Expanded Access Data ‘Defy Logic’

  Participants in trials of BrainStorm Cell Therapeutics’ NurOwn filed a Citizens’ Petition with the FDA earlier this month seeking a new review of the stem cell therapy that was rejected in 2022 based on real-world data and 90% survival in an expanded access program.

  July 17, 2025

   · 

  9 min read

   · 

  Heather McKenzie
• 

  Job Trends

  Adapting in Uncertain Times: Biopharma Professionals Turn To Fractional Roles

  1 in 5 respondents either have had or do have a fractional role, according to a recent BioSpace poll, and over half are considering it. Two recruitment experts, a fractional worker and an aspiring fractional worker share their insights.

  July 17, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Job Trends

  6 Companies Hiring in Illinois

  Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.

  July 17, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Neuropsychiatric disorders

  Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy

  FDA reviewers flag “discordant results” in a briefing document published ahead of Friday’s advisory committee meeting for the partners’ application for the antipsychotic in post-traumatic stress disorder.

  July 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Tariffs

  Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near

  In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO Vas Narasimhan told reporters that for most medicines, it typically takes three to four years to completely relocate production.

  July 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Report: U.S. Life Sciences Job Market Report Q2 2025

  The life sciences job market continues to shift. BioSpace’s Q2 2025 U.S. Life Sciences Job Market Report is now available, offering exclusive insights into the latest hiring trends, layoffs, and workforce dynamics across the life sciences industry.
  

  July 17, 2025

   · 

  1 min read

   · 

  BioSpace Insights
• 

  IN PARTNERSHIP WITH IQVIA

  AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace

  In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the evolving role of local qualified persons for pharmacovigilance with ⁠Ana Pedro Jesuíno⁠, global head local QPPV network at IQVIA.

  July 17, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Layoffs

  Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

  Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant pipeline shift and adding a black box warning to its Duchenne muscular dystrophy gene therapy Elevidys.

  July 17, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Government

  CDER Employees Leave FDA in Droves Amid HHS Overhaul

  In the first six months of 2025, 385 employees resigned from the Center for Drug Evaluation and Research, compared with under 130 staff during the same period last year.

  July 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Pricing

  BMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price

  In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer pitched the direct-to-consumer program as a way to allow uninsured, underinsured and self-pay patients to pay less out of pocket.

  July 17, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor